Overview

Prospective Observation Study of Insulin Sensitivity During and After Gonadotropin Releasing Hormone Agonist Therapy for Prostate Cancer

Status:
Completed

Trial end date:
2012-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this research study is to find out if a certain type of hormone therapy, gonadotropin-releasing hormone agonist (GnRH agonist), affects the way the body produces and responds to insulin. The investigators will evaluate the changes in insulin sensitivity during and after GnRH agonist treatment for prostate cancer. The investigators are assessing the possibility that treatment-related insulin resistance may contribute to the risk of diabetes and/or cardiovascular disease in men with prostate cancer.

Details

Lead Sponsor:

Massachusetts General Hospital

Collaborator:

National Institutes of Health (NIH)

Treatments:

Hormones
Insulin